A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement
Completed
Conditions studied: Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
In brief
The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked polyethylene
Key facts
- Study ID
- NCT00698152
- Run by
- Zimmer Biomet
- People needed
- 149
- Starts
- 2006-01-23
- Expected to finish
- 2016-01-15
- Last updated by the study team
- 2020-03-30
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Non inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid Arthritis
- Correction of Functional Deformity
- Treatment of non-union, femoral neck fractures, trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
- Revision of previously failed total hip arthroplasty
- Uncemented applications
You may not qualify if…
- Absolute contraindications
- Infection, sepsis and osteomyelitis
- Relative contraindications
- Uncooperative patient or patient with neurologic disorders who are incapable of following directions
- Osteoporosis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may be spread to the implant site
- Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
- Vascular insufficiency, muscular atrophy or neuromuscular disease
Where it is running
- The Orthopaedic Center — Rockville, Maryland, United States
- The Orthopaedic Institute of Ohio — Lima, Ohio, United States
- Ohio Valley Orthopedic and Sports Medicine — West Chester, Ohio, United States
- Scranton Orthopaedic Specialists, PC — Dickson City, Pennsylvania, United States
- Texas Orthopedic Specialists, PA — Grapevine, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.